| BC | Breast Cancer |
| miRNA | MicroRNA |
| Bak1 | Pro-apoptotic Bcl2 antagonist killer 1 |
| DAPK2 | Death-Associated kinase 2 |
| TSP-1 | Thrombospondin-1 |
| MCL-1 | Myeloid cell leukemia |
| EIF4E | Eukaryotic translation initiation factor 4E |
| CP110 | Centriolar coiled-coil protein 110 |
| APC4 | Anaphase promoting complex subunit 4 |
| HSPG2 | Heparin sulfate proteoglycan 2 |
| CCND1 | Cyclin D1 |
| PTEN | Phosphatase and tensin homolog |
| ERα | Estrogen receptor α |
| SERDs | Selective estrogen receptor downregulators |
| SERMs | Selective ER modulators |
| TCGA | The cancer genome atlas |
| ASCO | American society of clinical oncology |
| GEMIN4 | Gem nuclear organelle associated protein 4 |
| BMP7 | Bone morphogenetic protein 7 |
| UCP2 | Uncoupling protein 2 |
| HDAC4 | Histone deacetylase |
| SOC6 | Suppressor of cytokine signaling 6 |
| HER2 | Human epidermal growth factor receptor-2 |
| EMT | Epithelial to mesenchymal transition |
| IGF1R | Insulin-like growth factor-1 receptor |
| TKI | Tyrosine kinase inhibitor |
| FDA | Food and drug administration |
| CCNJ | Cyclin J |
| FUBP1 | Far upstream element binding protein 1 |
| TNBC | Triple negative breast cancer |
| IL-6 | Interleukine-6 |